Recent Legal Developments in Patent Law and Drug Pricing Negotiations
This week, significant legal developments emerged in the realm of patent law and drug pricing negotiations. The Fifth Circuit Court of Appeals dismissed an appeal from the Pharmaceutical Research and Manufacturers of America (PhRMA) and other drug industry organizations regarding the Medicare drug negotiation program established under the Inflation Reduction Act (IRA). The court affirmed the lower court's ruling, stating that the IRA does not violate constitutional principles, including the non-delegation doctrine and the Eighth Amendment's excessive fines clause.
In another notable case, the Federal Circuit transferred T-Mobile's appeal concerning KAIFI LLC's breach of contract counterclaims to the Fifth Circuit. The Federal Circuit determined it lacked jurisdiction over the appeal, as the matter pertained to state contract law rather than federal patent law. This ruling underscores the complexities of jurisdictional issues in patent-related cases.
Market Reading & Resources
Sponsor funding complete. Trade on.
Additionally, the Federal Circuit upheld a dismissal of a patent infringement complaint against Bath & Body Works, citing improper venue and patent ineligibility. The court emphasized that subject matter eligibility can be addressed prior to venue issues, reinforcing judicial economy in patent litigation.
The Computer & Communications Industry Association (CCIA) has urged the U.S. Supreme Court to take up a case involving Tesla and Granite Vehicle Ventures, which addresses discretionary denial considerations at the Patent Trial and Appeal Board (PTAB). This case is seen as pivotal in the ongoing battle against so-called "patent trolls."
The Ninth Circuit also denied Boeing's attempt to transfer a trade secret misappropriation case to the Federal Circuit, affirming that the patent inventorship claims raised by Boeing were not compulsory.
Lastly, the D.C. Circuit reversed a ruling regarding the FDA's causation standard in assessing market exclusivity for a generic drug, highlighting the intricate relationship between regulatory guidance and market approval processes. These cases collectively illustrate the evolving landscape of patent law and its intersection with drug pricing policies, reflecting ongoing tensions in the legal system.




